Abstract: A method for forming a subterranean thermal pathway includes injecting an initial fluid into a subterranean heat reservoir at a pressure above reservoir stress to create an opening of defined width. A slurry containing thermal particles in a carrier fluid is then injected into the opening to form a particle pack. Injection of the slurry is ceased, allowing the particle pack to be compressed under a particle pack stress load determined from the reservoir stress and slurry fluid pressure. The method ensures that the combined effect of opening width reduction under increasing stress to full closure stress, and the resulting increase in particle pack volume fraction, achieves or exceeds a target thermal pathway width. The target width is met by selecting particle size, compressive behavior, and initial solid volume fraction so the pack becomes the thermal pathway at full closure stress.

Abstract: Provided in the present invention are a salt of a benzothiazole compound as represented by formula I and a crystal form and the use thereof. The salt is selected from pamoate and palmitate. Further provided is the use of the salt of the compound of formula I and the crystal form thereof in the preparation of a drug for treating Parkinson's disease and restless leg syndrome.

Abstract: The present invention relates to a pyrazole compound and a preparation method therefor and a use thereof. In particular, the present invention relates to a compound shown in Formula I, a pharmaceutical composition containing same or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof.

Abstract: A slurry for enhancing geothermal recovery in a subterranean heat reservoir comprises thermal particles and a carrier fluid. The thermal particles have a selected volume, composition and physical properties sufficient to form a thermal pathway in the reservoir with a particle pack thermal conductivity that meets or exceeds a target thermal conductivity at a thermal pathway stress load of the reservoir. The carrier fluid has a selected fluid volume and viscosity sufficient for the slurry to be injected into openings of the reservoir at an injection pressure higher than the reservoir stress value.

Abstract: The present application provides a method for preparing a drug-linker conjugate. Specifically, the present application provides a method for preparing compound IM2, which comprises the following steps: adding compound SM1 to a mixed solution of triphosgene and 4-dimethylaminopyridine to obtain an intermediate solution; adding compound SM2 to the intermediate solution, stirring the mixture, thereby obtaining compound IM2. The stability, practicality and scalability of the process are improved by optimizing the preparation process of IM2 and using a normal chromatography purification method that is easily scalable.

Abstract: A heavy oil or bitumen or mixtures of heavy oil and bitumen or mixtures of a dilutant and heavy oil or bitumen is treated to separate components of the feed oil and induce reactions that crack the heavy oil or bitumen into light components. A heated inclined dual tube unit arrangement where feed oil enters the arrangement through the inner tube and which opens partway up the outer tube. Vaporized oil continues to flow up within the outer tube whereas the liquid oil product flows down the annular space between the inner and outer tubes. The vaporized oil is condensed beyond the dual tube arrangement to yield liquid oil products. Heat exchange can be done between the products and the inlet feed oil to improve the energy efficiency of the unit.

Abstract: Provided are a salt and a crystal form of a pyrimidine compound, and preparation methods therefor. Specifically, provided are a salt and a crystal form of a compound I, including a crystal form of the salt, and preparation methods therefor.

Abstract: The present disclosure provides a method for determining a frequency domain resource, performed by an evolved reduced capability (eRedCap) terminal. The method includes: determining a mapping rule of virtual resource block (VRB)-to-physical resource block (PRB) supported by a physical downlink shared channel (PDSCH), wherein the mapping rule includes that interleaved mapping is not supported, or the mapping rule is a first interleaved mapping rule; and determining a physical frequency domain resource occupied by the PDSCH according to the mapping rule supported by the PDSCH and VRBs.

Abstract: A beam prediction method is performed by a terminal and includes: determining beam quality of partial beam pairs in first receiving beam groups, wherein the first receiving beam groups belong to receiving beam groups corresponding to receiving beams supported by the terminal; and predicting an optimal beam or beam quality of all beam pairs in the first receiving beam groups by inputting the beam quality of the partial beam pairs in the first receiving beam groups into a beam prediction model; wherein the beam prediction model is obtained through pre-training based on beam quality of beam pairs in second receiving beam groups, the second receiving beam groups belong to the receiving beam groups corresponding to the receiving beams supported by the terminal, and the second receiving beam groups are same as or different from the first receiving beam groups.

Abstract: Provided in the present invention are a salt of a benzothiazole compound as represented by formula I and a crystal form and the use thereof. The salt is selected from pamoate and palmitate. Further provided is the use of the salt of the compound of formula I and the crystal form thereof in the preparation of a drug for treating Parkinson's disease and restless leg syndrome.

Abstract: A pre-shared key (PSK) updating method is disclosed. A first communication apparatus stores a first PSK for processing, within an aging periodicity of the first PSK, a packet exchanged between the first communication apparatus and a second communication apparatus. The first communication apparatus may receive, within the aging periodicity of the first PSK, a first protocol packet that is sent by the second communication apparatus and includes a first PSK key material for generating a second PSK. The second PSK is for processing, within an aging periodicity of the second PSK, a packet exchanged between the first communication apparatus and the second communication apparatus.

Abstract: The thermally responsive actuator described in this disclosure includes a housing, a thermal expansion material, a piston, and a closure assembly. The housing has an internal cavity and an opening that leads into the cavity. The thermal expansion material is placed inside the cavity. The piston extends at least partially through the opening into the cavity. The closure assembly, which includes a cover and a sealing system, is attached to the housing at the opening. It covers the opening and surrounds the piston. The sealing system includes two sealing members: a first and a second. The housing and/or the cover has two separate compartments—one for each sealing member—positioned along the same axis but separated by the cover.

Abstract: The present disclosure discloses a proportional regulating valve, including: a housing, a valve core, and a sealing device. The sealing device and the valve core are configured such that an effective operating angle of the valve core is greater than the sum of respective central angles of two housing outlets of the at least two housing outlets, and the effective operating angle of the valve core is an angle of rotation that enables the valve core outlet to be in communication with both of the two housing outlets and that changes the opening degree of at least one of the housing outlets.

Abstract: The present invention belongs to the technical field of biomedicine, and relates to a method for treating cancer by using an antibody-drug conjugate. In particular, the present invention relates to a use of an antibody drug conjugate represented by formula (I) and a pharmaceutically acceptable salt, a stereoisomer or a metabolite thereof, or a solvate of the foregoing in the manufacture of a medicament for preventing and/or treating a HER2-expressing, amplified or mutated cancer, wherein A is a group obtained by removing n amino groups from an antibody against HER2 or an active fragment or variant thereof; preferably, A is trastuzumab or a group obtained by removing n amino groups from Pertuzumab; n is selected from 1-10, such as 2-10 or 2-8; and preferably, n is an integer of 1, 2, 3, 4, 5, 6, 7 or 8.

Abstract: The present application relates to the field of treatment of diseases, and in particular, to an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Therefore, the present application further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs, wherein the drugs are used for the prevention and/or treatment of tumors.

Abstract: Methods, system, and non-transitory processor-readable storage medium for a test selection system are provided herein. An example method includes selecting, by a test selection system, a regression test case from a plurality of regression test cases in a software testing lifecycle system. The test selection system determines a product release weight associated with the regression test case, where the product release weight incorporates new features associated with a product release. The test selection system obtains a regression test case value for the regression test case by applying the product release weight. The test selection system selects the regression test case for use in regression testing for the product release, based on the regression test case value and executes the regression test case on a system.

Abstract: The present invention relates to a use of a heterocyclic compound represented by formula I in the preparation of a drug for treating or assisting the treatment of diseases or conditions in an individual relating to a rearranged during transfection (RET) drug-resistant mutation and a treatment method using said heterocyclic compound.

Abstract: The present invention relates to the field of biomedicine, and in particular, the present invention relates to an antibody or antigen-binding fragment thereof which specifically binds to MSLN, and a chimeric antigen receptor (CAR) comprising said antibody or antigen-binding fragment thereof. The present invention also relates to modified immune cells expressing said CAR, or co-expressing said CAR and additional bioactive molecules (e.g. PD-1 antibody and/or mIL-15), and a method for preparing said modified immune cells.

Abstract: The present application belongs to the technical field of communications. Disclosed are a beam prediction method and apparatus, and a device and a storage medium. The method includes: inputting, into a first beam prediction model, the beam quality of a first transmit beam which is obtained on the basis of a first receive beam, and obtaining, by means of the first beam prediction model, the beam quality of a second transmit beam based on the first receive beam, wherein the first receive beam is one of n receive beams of a terminal, and the first transmit beam comprises one or more transmit beams corresponding to the first receive beam; and reporting, to a network device, the beam quality of at least one of the first transmit beam and the second transmit beam.

Abstract: Spirocyclic compounds, including chiral spiro diamine, chiral spiro amino naphthol, chiral spiro bis(indole), chiral spiro diaryl diol, chiral spiro diaryl diamine, chiral spiro amino naphthol, chiral spiro diaryl diindole, and chiral spiro phospholane useful as chiral ligands and chiral organocatalysts and methods of preparation and methods of use thereof. Owing to the molecular shape and three-dimensional orientation, the chiral diamine and chiral amino naphthol molecules provide a skeleton for use as ligands and organocatalysts.